Patent US5411940A successfully refreshed from Google Patents.
US5411940A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Use of TGF-β3 to reduce the formation of scar tissue in response to corneal trauma
Assignee: Alcon Research LLC
•
Filing: 1993-09-29
•
Granted: 1995-05-02
•
Expires: 2013-09-29
Abstract
Abstract The use of TGF-β 3 to reduce the formation of scar tissue as a result of trauma to the cornea of the eye is described. The invention is particularly directed to the use of TGF-β 3 to reduce the formation of scar tissue in connection with ophthalmic surgical procedures involving the cornea, such as laser irradiation of the cornea. A composition containing TGF-β 3 is applied to the site of the trauma to alter the production and composition of extracellular matrix synthesized by fibroblasts, and thereby reduce the formation of scar tissue and consequent impairment of vision.
Inventors
- 👤 Jon C. Nixon
- 👤 Billie M. York
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 12:08
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/18; A61K38/1841
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
43 words
A method of reducing the formation of scar tissue following trauma to the cornea, which comprises applying to the cornea at the site of the trauma a composition comprising: 0.001 to 10.000 ng/ml of TGF-β 3 ; and a pharmaceutically acceptable vehicle therefor.
Claim 2
Independent Claim
43 words
A method of reducing the formation of scar tissue following trauma to the cornea, which comprises applying to the cornea at the site of the trauma a composition comprising: 0.001 to 10.000 ng/ml of TGF-β 3 ; and a pharmaceutically acceptable vehicle therefor.
Claim 3
Dependent Claim
32 words
A method according to claim 1, wherein the trauma resulted from an ophthalmic surgical procedure, and the composition is topically applied to the site of the trauma in conjunction with said procedure.
Claim 4
Dependent Claim
15 words
A method according to the claim 2, wherein the surgical procedure comprises a refractive surgery.
Claim 5
Dependent Claim
16 words
A method according to claim 3, wherein the refractive surgery comprises laser irradiation of the cornea.
Claim 6
Dependent Claim
21 words
A method according to claim 4, wherein the refractive surgery comprises irradiation of at least a portion of the corneal epithelium.
Claim 7
Dependent Claim
22 words
A method according to claim 4, wherein the refractive surgery comprises debridement of the corneal epithelium, followed by irradiation of the stroma.
Claim 8
Dependent Claim
13 words
A method according to claim 1, wherein the TGF-β 3 is human derived.
References Cited (Backward Citations)
US4981841A
Cited
US4983580A
Cited
US4962091A
Cited
US4717717A
Cited
US5057494A
Cited
US5124392A
Cited
US5061786A
Cited
US5108989A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1998-05-01 | 1998-10-31 | 1999-05-02 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2002-05-01 | 2002-10-31 | 2003-05-02 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2006-05-01 | 2006-10-31 | 2007-05-02 | $7700.00 | Window Closed / Lapsed |